I re-read some of what you’ve posted previously - some good stuff in there - and further to my post above it’d be interesting to know if Janssen are using the test as a means to better understand where the greatest benefit for their drug lies based on the CREDENCE trial population.
If some Type 2 patients are unlikely to develop CKD then the drug would show no benefit. Meaning their kidney function would not change as a result of treatment.
So restricting the analysis to a sub group of patients in the trial i.e. those shown as likely to develop CKD based on the test - would amplify the significance of the result.
Apologies for the somewhat repetitive rambling - but PIQ is piquing my interest this afternoon.
PIQ Price at posting:
30.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)